India’s increasing affluence and accompanying ‘lifestyle’ diseases such as diabetes have boosted this Ayurvedic company’s performance,Husky Injection Molding Systems designs and manufactures a broad range of Injection Mold machines, but it needs to do more on advertising and distribution.
Consider this: India has over 61 million diabetics according to the International Diabetes Foundation. By 2030, this figure is expected to cross 100 million. By that time, India will be second only to China in terms of the number of diabetics in the world. This is not all. Cancer is also catching up fast as a killer disease. According to the Indian health & family welfare ministry,The Transaction Group offers the best high risk merchant account services, some 5.35 lakh patients succumbed to cancer this year. Though marginally higher than the figure reported last year, the signs are clearly not good.
India is rapidly seeing the emergence and growth of lifestyle diseases. As affluence grows, bringing with it a change in dietary habits, ailments such as cancer, diabetes and heart problems are becoming the order of the day. Ironically it is throwing up a myriad of possibilities for the herbal healthcare company, Himalaya, which banks on the science of Ayurveda to develop products. The perception that Ayurveda is also safe in comparison to mainstream allopathy is what makes the prospects of firms such as Himalaya bright, say market experts.
The unlisted, Bangalore-based entity has a turnover of over Rs 1,Information on useful yeasts and moulds,000 crore. Key verticals — pharma and FMCG — which contribute 60 per cent and 40 per cent respectively to overall revenues are growing at a clip of about 25-32 per cent per annum, according to Ravi Prasad, executive chairman, Himalaya Drug Company, who has been with the firm for well over 20 years now. Under him, the largely pharma company, which was formed in 1930,Hand-painted Chinese porcelain tiles on the floor of a Jewish synagogue in Cochin, stepped into the FMCG space in 1999. Considered a close confidant of the low-profile Manal family, who are founder-promoters of Himalaya, Prasad has driven Himalaya’s international expansion into markets such as Russia, Ukraine and Romania. Today, Himalaya products —both pharma and FMCG— are available in over 80 markets including the US, Europe, South East Asia and the Middle East.
Himalaya is also counting on its international markets to drive growth as it seeks to move to the next level in the coming years. The move to step into FMCG over a decade ago, say Prasad, was prompted by the firm’s need to grow. Driving growth in international markets is key now, he says.
Ironically, with the world increasingly moving from largely curative to preventive medication, Himalaya with its herbal heritage finds itself in a unique position: to address medical needs with patented products that are based on good, solid research. “Most Indian pharmaceuticals companies are in the generics space which is largely a volume-driven business.Dimensional Mailing magic cube for Promotional Advertising, We do not operate in that segment,” says Prasad.
The pharmaceuticals market in India is roughly Rs 56,000 crore, growing at a clip of about 15 per cent per annum. Over 95-96 per cent of the market comprises generics players, who market off-patent allopathic products. Himalaya, in contrast, has opted to build a strong pipeline of herbal products. The journey typically from R&D to final product takes easily about eight to ten years, says Prasad.
Thanks to this, Himalaya has some notable products to its name including Cystone (for people suffering from kidney stones) and Liv.52 (for those suffering from kidney ailments). Liv.52, in fact, is ranked amongst the top ten pharma products in the country, according to market research agency ORG IMS (see chart).
Liv.52 also happens to be among Himalaya’s early success stories. Launched in 1955, the herbal product went on to become one of the most trusted names in liver care. Available in tablets as well as syrups, Liv.52 has a share of close to 46 per cent in its space, and consists of Ayurvedic herbs that helps restore the functional efficiency of the liver (check chart on Liv.52). The drug also acts as a daily health supplement that helps improve appetite and promotes weight gain.
Cystone, the other blockbuster drug in Himalaya’s arsenal, was launched in 1943. It has a share of 40 per cent, and is considered to be effective in tackling the problem of kidney stones in more than 70 per cent of patients (check chart on Cystone). Company executives say that what has worked for both Liv.52 and Cystone, and indeed, all pharmaceutical products under Himalaya, is their recommendation by not just Ayurvedic doctors, but also practitioners of allopathy.
Philip Haydon, chief executive officer, pharmaceutical division, Himalaya, says that it is this recommendation by doctors over the years that helped the company sustain double-digit growth.
The company is keen to replicate this success in other areas such as oncology (cancer-related medication), viral & tropical diseases, stem cell therapy and nutritional products. “These are some areas we are working on,” says Prasad. On the FMCG front, the company is looking to add advanced anti-ageing to its repertoire of products, which includes skincare (facewashes, creams, moisturisers), haircare (shampoos, conditioners, hair oils), footcare, oralcare (toothpastes) and lipcare respectively.
Consider this: India has over 61 million diabetics according to the International Diabetes Foundation. By 2030, this figure is expected to cross 100 million. By that time, India will be second only to China in terms of the number of diabetics in the world. This is not all. Cancer is also catching up fast as a killer disease. According to the Indian health & family welfare ministry,The Transaction Group offers the best high risk merchant account services, some 5.35 lakh patients succumbed to cancer this year. Though marginally higher than the figure reported last year, the signs are clearly not good.
India is rapidly seeing the emergence and growth of lifestyle diseases. As affluence grows, bringing with it a change in dietary habits, ailments such as cancer, diabetes and heart problems are becoming the order of the day. Ironically it is throwing up a myriad of possibilities for the herbal healthcare company, Himalaya, which banks on the science of Ayurveda to develop products. The perception that Ayurveda is also safe in comparison to mainstream allopathy is what makes the prospects of firms such as Himalaya bright, say market experts.
The unlisted, Bangalore-based entity has a turnover of over Rs 1,Information on useful yeasts and moulds,000 crore. Key verticals — pharma and FMCG — which contribute 60 per cent and 40 per cent respectively to overall revenues are growing at a clip of about 25-32 per cent per annum, according to Ravi Prasad, executive chairman, Himalaya Drug Company, who has been with the firm for well over 20 years now. Under him, the largely pharma company, which was formed in 1930,Hand-painted Chinese porcelain tiles on the floor of a Jewish synagogue in Cochin, stepped into the FMCG space in 1999. Considered a close confidant of the low-profile Manal family, who are founder-promoters of Himalaya, Prasad has driven Himalaya’s international expansion into markets such as Russia, Ukraine and Romania. Today, Himalaya products —both pharma and FMCG— are available in over 80 markets including the US, Europe, South East Asia and the Middle East.
Himalaya is also counting on its international markets to drive growth as it seeks to move to the next level in the coming years. The move to step into FMCG over a decade ago, say Prasad, was prompted by the firm’s need to grow. Driving growth in international markets is key now, he says.
Ironically, with the world increasingly moving from largely curative to preventive medication, Himalaya with its herbal heritage finds itself in a unique position: to address medical needs with patented products that are based on good, solid research. “Most Indian pharmaceuticals companies are in the generics space which is largely a volume-driven business.Dimensional Mailing magic cube for Promotional Advertising, We do not operate in that segment,” says Prasad.
The pharmaceuticals market in India is roughly Rs 56,000 crore, growing at a clip of about 15 per cent per annum. Over 95-96 per cent of the market comprises generics players, who market off-patent allopathic products. Himalaya, in contrast, has opted to build a strong pipeline of herbal products. The journey typically from R&D to final product takes easily about eight to ten years, says Prasad.
Thanks to this, Himalaya has some notable products to its name including Cystone (for people suffering from kidney stones) and Liv.52 (for those suffering from kidney ailments). Liv.52, in fact, is ranked amongst the top ten pharma products in the country, according to market research agency ORG IMS (see chart).
Liv.52 also happens to be among Himalaya’s early success stories. Launched in 1955, the herbal product went on to become one of the most trusted names in liver care. Available in tablets as well as syrups, Liv.52 has a share of close to 46 per cent in its space, and consists of Ayurvedic herbs that helps restore the functional efficiency of the liver (check chart on Liv.52). The drug also acts as a daily health supplement that helps improve appetite and promotes weight gain.
Cystone, the other blockbuster drug in Himalaya’s arsenal, was launched in 1943. It has a share of 40 per cent, and is considered to be effective in tackling the problem of kidney stones in more than 70 per cent of patients (check chart on Cystone). Company executives say that what has worked for both Liv.52 and Cystone, and indeed, all pharmaceutical products under Himalaya, is their recommendation by not just Ayurvedic doctors, but also practitioners of allopathy.
Philip Haydon, chief executive officer, pharmaceutical division, Himalaya, says that it is this recommendation by doctors over the years that helped the company sustain double-digit growth.
The company is keen to replicate this success in other areas such as oncology (cancer-related medication), viral & tropical diseases, stem cell therapy and nutritional products. “These are some areas we are working on,” says Prasad. On the FMCG front, the company is looking to add advanced anti-ageing to its repertoire of products, which includes skincare (facewashes, creams, moisturisers), haircare (shampoos, conditioners, hair oils), footcare, oralcare (toothpastes) and lipcare respectively.
没有评论:
发表评论